The conformational conversion of the prion protein, a sialoglycoprotein containing two N-linked oligosaccharide chains, from its normal form (PrP C ) to a pathogenic form (PrP Sc ) is the central causative event in prion diseases. Although PrP Sc can be generated in the absence of glycosylation, there is evidence that oligosaccharide chains may modulate the efficiency of the conversion process, and may also serve as molecular markers of diverse prion strains. In addition, mutational inactivation of one of the N-glycosylation sites has recently been associated with a familial spongiform encephalopathy. To investigate the role of N-glycans in determining the properties of PrP, we have expressed in transfected Chinese hamster ovary cells mouse PrP molecules in which N-glycosylation has been blocked either by treatment with the drug tunicamycin, or by substitution of alanine for threonine at one or both of the N-X-T consensus sites. We report that PrP molecules mutated at Thr 182 alone or at both Thr 182 and Thr 196 fail to reach the cell surface after synthesis, but that those mutated at Thr 196 or synthesized in the presence of tunicamycin can be detected on the plasma membrane. We also find that all three mutant PrPs, and to a limited extent wild-type PrP synthesized in the presence of inhibitor, acquire biochemical attributes reminiscent of PrP Sc . We suggest that the PrP molecule has an intrinsic tendency to acquire some PrP Sc -like properties, and that N-glycan chains protect against this change. However, pathogenic mutations, or presumably contact with exogenous prions, are necessary to fully convert the protein to a PrP Sc state.
Prion diseases are fatal neurodegenerative disorders of human beings and animals which have attracted enormous attention among both scientists and the public. The recent emergence of a variant form of Creutzfeldt-Jakob disease in the United Kingdom and France has raised widespread concern that human beings can be infected by consumption of beef from cows afflicted with bovine spongiform encephalopathy, a prion disease of cattle (1) . The chemical nature of the infectious agent that causes these diseases has also been the subject of intense interest. Current evidence indicates that this unusual agent, which has been called a prion to distinguish it from a conventional virus, consists primarily of a single kind of protein molecule designated PrP Sc (2) . PrP Sc is thought to be a conformationally altered isoform of a host-encoded membrane glycoprotein called PrP C . Both isoforms of PrP appear to have the same amino acid sequence (3) , and contain similar covalent modifications, including a single disulfide bond (4) , two complex-type N-linked oligosaccharide chains (5, 6) , and a C-terminal glycosylphosphatidylinositol (GPI) 1 anchor (7). The molecular mechanism by which PrP C is converted into PrP Sc is unknown, but may involve transitions of ␣-helices to ␤-sheets in critical regions of the polypeptide chain (8) . This same conformational transformation is thought to underlie familial prion diseases which are linked to mutations in the gene encoding PrP (9) , as well as sporadic prion diseases which have no clear infectious or genetic etiology.
Mammalian PrP contains two consensus sites for N-linked glycosylation (at asparagine residues 181 and 197 in human and hamster PrP, and residues 180 and 196 in mouse PrP).
Detailed chemical analysis of the carbohydrate chains of PrP
Sc purified from scrapie-infected hamster brain has shown that both consensus sites are utilized, and that a mixture of bi-, tri-, and tetra-antennary complex-type oligosaccharide chains is present, with about 70% of the terminal galactose residues linked to sialic acid (5, 6) . Much less is known about the carbohydrate chains of PrP C , which is much more difficult to purify in large amounts, but it appears that this isoform also has two asparagine-linked, complex-type chains containing sialic acid (5) . Biosynthetically mature PrP appears as three bands on SDS-polyacrylamide gels, thought to correspond to molecules with 0, 1, or 2 N-linked oligosaccharide chains, with the glycosylated species migrating as broad bands due to heterogeneous modification of their core oligosaccharides (10 -13) .
Because of the well known role of glycosylation in folding and maturation of nascent polypeptide chains (14) , it is reasonable to suppose that N-linked oligosaccharide chains might play some role in the conformational transition that is responsible for generation of PrP Sc . A molecule in which both consensus sites for N-glycosylation are mutated is capable of being converted into PrP Sc , as is PrP synthesized in the presence of the glycosylation inhibitor tunicamycin (15) . These results indicate that N-linked glycans are not essential for the conversion process. However, several pieces of evidence indicate that glycan chains may modulate the efficiency with which PrP Sc is formed. First, Taraboulos et al. (15) found that PrP Sc is produced more rapidly when scrapie-infected cells are treated with tunicamycin. Second, several investigators have observed that PrP Sc * This work was supported by National Institutes of Health Grant NS35496 (to D. A. H.) and a grant from the Missouri Alzheimer's Association (to S. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. synthesized in scrapie-infected cells displays a preponderance of lower molecular weight glycoforms (13, 16) . This suggests that less glycosylated molecules may be preferred substrates in the generation of PrP Sc , an interpretation consistent with studies on the in vitro conversion of unglycosylated PrP C into PrP Sc (17) . Third, an inherited form of spongiform encephalopathy has recently been described in a Brazilian family with an threonine 3 alanine substitution at codon 183 which abolishes one of the consensus sites for glycosylation (18) . Taken together, these results raise the possibility that the absence of oligosaccharide chains on the PrP molecule may actually increase the efficiency with which PrP Sc is formed. The pattern of PrP glycosylation also appears to be an important marker of prion strain variation. Kascsak et al. (19) noted differences in the immunoblot pattern of PrP species derived from several different rodent scrapie strains. More recently, Parchi et al. (20) have characterized two different PrP Sc strains in patients with sporadic Creutzfeldt-Jakob disease that differ in the size and glycosylation pattern of the core fragment (PrP 27-30) produced after protease digestion. Collinge et al. (21) have expanded this classification to include infectious forms of Creutzfeldt-Jakob disease. They report that the PrP 27-30 molecules associated with "new variant" Creutzfeldt-Jakob disease and with bovine spongiform encephalopathy display the same M r and preponderance of the doubly glycosylated isoform, raising the possibility that the BSE agent may have been transmitted to humans. Variations in molecular size and glycoform distribution also characterize PrP 27-30 molecules prepared from the brains of patients with familial prion diseases (22) , and we have reported a similar phenomenon in mutant PrP molecules expressed in cultured cells (23) . It has been suggested that differences in glycosylation may not only be markers of prion strain variation, but may actually play a causal role in the propagation of strains by targeting each prion variant to distinctive subpopulation of neurons in the brain (24) .
Given the likely importance of N-glycosylation to prion biology as suggested by these results, we decided to undertake a detailed analysis of the biosynthesis in cultured cells of PrP molecules that were aberrantly glycosylated, either as a result of mutation of one or both of the glycosylation consensus sites, or because of synthesis in the presence of the inhibitor tunicamycin. One of the mutations we have examined is homologous to the threonine 3 alanine substitution at codon 183 that is associated with spongiform encephalopathy in the Brazilian family (18) . A homologous set of mutations has been examined by Rogers et al. (25) for their effects on trafficking of hamster PrP in CV1 cells. In view of the evidence cited above that absence of glycosylation may improve PrP as a substrate for generation of PrP Sc , we were particularly interested in determining whether the abnormally glycosylated molecules would convert spontaneously to a PrP Sc -like state. This question was also a natural one to ask, given our previous work in which we showed that PrP molecules carrying other disease-associated mutations acquire all of the biochemical hallmarks of PrP Sc when expressed in cultured Chinese hamster ovary (CHO) cells (11, 23, 26, 27) . We report here that mutation of either one or both of the consensus sites for N-glycosylation induced PrP to acquire all of the biochemical properties of PrP Sc . Surprisingly, even wild-type PrP acquired some of these properties, although to a more limited extent, when glycosylation was inhibited with tunicamycin.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies-Cell culture reagents were from the Tissue Culture Support Center at Washington University, N-Glycosidase F and tunicamycin from Boehringer Mannheim, sulfo-biotin-X-NHS from Calbiochem, [ 35 S]methionine (Pro-mix, 1,000 Ci/mmol) from Amersham, and fluorescein-conjugated secondary antibodies from Cappel. All other reagents were from Sigma. Phosphatidylinositol-specific phospholipase C (PIPLC) from Bacillus thuringiensis was prepared as described previously (28) .
Mouse monoclonal antibody 3F4 (29) and rabbit polyclonal antibody 78295, raised against PrP 27-30 from scrapie-infected hamster and mouse brain, respectively, were gifts from Dr. Rick Kascsak. Although both of these antibodies react with hamster PrP, CHO cells do not synthesize detectable levels of endogenous hamster PrP, 2 so that only recombinant moPrP is detected in this cell type.
PrP Constructs-T182A and T198A mutations were obtained by polymerase chain reaction using the following primers: 5Ј-GACCA-GAAGCTTATGGCGAACCTTGGCTACTGG-3Ј (primer 1), 5Ј-GACCG-TGTGCTGCTTGATGGCGATATTGACGCAGTCGTG-3Ј (primer 2), 5Ј-CATCTTCACATCGGTCTCGGCGAAGTTCTCCCCCTTGGT-3Ј (primer 3), 5Ј-GACCAGGGATCCTCATCCCACGATCAGGAAGAT-3Ј (primer 4), 5Ј-CACGACTGCGTCAATATCGCCATCAAGCAGCACACGGTC-3Ј (primer 5), and 5Ј-ACCAAGGGGGAGAACTTCGCCGAGACCGATGT-GAAGATG-3Ј (primer 6). The 5Ј-half of a 3F4-tagged wild-type moPrP cDNA (11) was amplified with primers 1 and 2 (T182A), or with primers 1 and 3 (T198A). The 3Ј-half of the same cDNA was amplified with primers 4 and 5 (T182A), or with primers 4 and 6 (T198A). 5Ј and 3Ј polymerase chain reaction products were then mixed, and amplified again with primers 1 and 4. After cleavage with HindIII and BamHI, the secondary polymerase chain reaction products were cloned into pBC12/CMV (30) that had been cleaved with the same two enzymes. The T182A/T198A construct was obtained by introducing the T198A mutation into the T182A cDNA. The structure of each DNA construct was confirmed by sequencing.
Cell Lines-CHO cells were grown in ␣-minimal essential medium containing 7.5% fetal calf serum, and penicillin/streptomycin in an atmosphere of 5% CO 2 , 95% air. CHO cells were transfected using Lipofectamine (Life Technologies, Inc.), according to the manufacturer's directions, with a 1:10 mixture of pRSVneo (31) and the pBC12/CMV expression plasmid encoding moPrP. Antibiotic-resistant clones were selected in 700 g/ml geneticin (G418), subcloned once, and maintained in 300 g/ml geneticin. The experiments reported here were carried out on a single cell line expressing each construct but results were confirmed on additional independent cell lines. The amount of proteaseresistant PrP did not change significantly during passage of the cells.
Metabolic Labeling and Immunoprecipitation-Confluent cultures of CHO cells were labeled in methionine-free minimal essential medium containing [ 35 S]methionine (Pro-mix; 250 -500 Ci/ml), and were chased in Opti-MEM (Life Technologies, Inc.). Cells were then lysed in a buffer that contained 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 0.5% Triton X-100, and 0.5% sodium deoxycholate, supplemented with protease inhibitors (pepstatin and leupeptin, 1 g/ml; phenylmethylsulfonyl fluoride, 0.5 mM; EDTA, 2 mM). Lysates were first clarified by centrifugation for 5 min at 16,000 ϫ g in a microcentrifuge, a procedure that removes debris but does not pellet significant amounts of PrP. Immunoprecipitation of PrP from clarified lysates was performed using monoclonal antibody 3F4 as described previously (11) . Immunoprecipitated proteins were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE).
Deglycosylation of PrP-Where indicated, cell lysates were treated prior to immunoprecipitation with 0.01 units/ml N-glycosidase F for 16 h at 37°C. For the experiments shown in Fig. 3 , immunoprecipitated PrP was eluted from protein A-Sepharose with 20 l of 50 mM sodium citrate (pH 5.5) containing 0.1% SDS, and then incubated for 16 h with either endoglycosidase H (1.6 milliunits) or neuraminidase (10 milliunits). After addition of 2 ϫ SDS sample buffer, samples were analyzed by SDS-PAGE.
Immunocytochemistry-Cells grown on glass coverslips were incubated with polyclonal antibody 78295 for 1 h at 4°C. After rinsing, cells were fixed with methanol for 30 min at 4°C, and then incubated with fluorescein-conjugated secondary antibody for 1 h at room temperature. Coverslips were mounted in glycerol, and cells observed with a Nikon Optiphot-2 fluorescence microscope.
Assay of Trypsin Accessibility-Metabolically labeled cells were rinsed with phosphate-buffered saline, and were either left untreated, or were incubated for 6 min at 4°C with 0.25% trypsin in phosphatebuffered saline followed by addition of fetal calf serum to 10% to terminate digestion. MoPrP was then immunoprecipitated from cell lysates with 3F4 antibody as described above.
Assay of PrP
Sc Properties-To assay detergent-insolubility, cleared lysates of metabolically labeled cells were centrifuged at 265,000 ϫ g for 40 min in the TLA 100.3 rotor of a Beckman Optima TL ultracentrifuge, and PrP in supernatant and pellet fractions recovered by immunoprecipitation. These conditions of centrifugation, which we have used in our previous studies of PrP synthesized in CHO cells, will sediment PrP Sc but not PrP C from brain (23, 26, 27) . To measure protease-resistance, proteins were methanol-precipitated from cell lysates, digested with proteinase K (3.3 g/ml for 10 min at 37°C) in Sarkosyl, methanol-precipitated a second time, and then analyzed for moPrP by immunoblotting using 3F4 antibody (27) . These conditions for protease digestion are identical to those used in our previous studies (23, 26, 27) . We have also previously employed 3F4 antibody to detect protease-resistant PrP on immunoblots (26, 27) ; similar results are obtained when antibody 78295 is used (data not shown).
To analyze PIPLC release, CHO cells were biotinylated with sulfobiotin-X-NHS as described by Shyng et al. (28) , and were then incubated with PIPLC (1 unit/ml in Opti-MEM) at 4°C for 2 h. MoPrP in incubation media and cell lysates was immunoprecipitated, separated by SDS-PAGE, and biotinylated moPrP visualized by developing blots of the gels using horseradish peroxidase-coupled streptavidin and enhanced chemiluminescence.
To assay hydrophobicity, metabolically labeled cells were solubilized for 20 min at 4°C in 1% Triton X-114 in phosphate-buffered saline containing protease inhibitors; the detergent was diluted from a 12% stock solution that had been precondensed according to Bordier (32) . After incubation at 37°C for 10 min, aqueous and detergent phases were separated by centrifugation. The detergent phase was diluted to the initial volume with phosphate-buffered saline, incubated with or without PIPLC for 2 h at 4°C, and the phase separation repeated. PrP in each phase was then recovered by immunoprecipitation.
RESULTS
Expression of Wild-type, T182A, T198A, and T182A/T198A moPrPs in Transfected CHO Cells-We have previously used CHO cells to express recombinant mouse PrP (moPrP), and have shown that in these cells PrP molecules carrying pathogenic mutations are converted to a PrP Sc -like state (11, 23, 26, 27) . For the present studies, we have analyzed stably transfected CHO cells that express wild-type moPrP, as well as moPrP molecules carrying mutations in the consensus sites for N-glycosylation. Like other mammalian PrPs, moPrP contains two consensus sites for asparagine-linked glycosylation (N-I-T and N-F-T, spanning residues 180 -182 and 196 -198, respectively). We constructed moPrP molecules containing either one or both of the following point mutations: T182A and T198A (Fig. 1 ). These mutations, by changing the third amino acid of the consensus sequence N-X-T, abolish utilization of the corresponding glycosylation site. All moPrP constructs were tagged with an epitope for the monoclonal antibody 3F4 to facilitate their detection in immunoblotting and immunoprecipitation experiments. . The singly and doubly glycosylated species migrate as broad bands on SDS-PAGE, presumably due to heterogeneous modification of their core oligosaccharides. Since the cells in this experiment had been labeled for 2.5 h and chased for 30 min, the bands represent the mature glycoforms. A similar pattern of glycosylation of wild-type PrP has been described in other cell types by a number of authors (10, 12, 13) .
The mutant moPrPs each displayed a distinctive pattern of glycosylation. T182A moPrP (Fig. 2, lane 3) appeared as a sharp band of 31 kDa representing the singly glycosylated species. The T198A protein (lane 5) migrated as a major band of 31 kDa corresponding to singly glycosylated molecules, and a minor band of 28 kDa corresponding to unglycosylated protein. The 31-kDa band was usually broad in appearance, with a faint smear extending above it, suggesting that this species, like the corresponding glycoform of wild-type moPrP, carried a single oligosaccharide chain with heterogeneous modifications of its core glycans. When both sites were mutated (T182A/T198A), the protein migrated at 28 kDa, although it was sometimes possible to detect a minor band of ϳ30 kDa (see lane 7 of Fig.  6B ) which may reflect glycosylation of a non-canonical site (25) .
Deglycosylation with N-glycosidase F resolved wild-type and mutant moPrPs into a single species of 28 kDa (Fig. 2, lanes 2,  4, 6, and 8) , corroborating the assumption that variations in molecular mass of the PrP species results from addition of N-linked glycan chains. Also consistent with this idea, wildtype PrP synthesized in the presence of tunicamycin migrated as a single PrP band of 28 kDa (lane 9). Tunicamycin inhibits the addition of GlcNAc to dolichol phosphate, the first step in construction of the core oligosaccharide structure that is transferred to the asparagine residue of polypeptides to be glycosylated.
T198A moPrP, but Not T182A moPrP, Is Susceptible to Digestion by Endoglycosidase H and Is Resistant to the Action of Neuraminidase-To follow maturation of the oligosaccharide chains of the recombinant moPrPs, we tested their susceptibility to digestion by endoglycosidase H (endo H) and neuraminidase (Fig. 3) . Complex N-linked oligosaccharides become resistant to the action of endo H in the mid-Golgi as a result of the activity of the enzyme mannosidase II, and if they contain sialic acid residues they become susceptible to attack by neuramini- dase in the trans-Golgi network where the enzyme sialyl transferase resides. When cells were pulse-labeled for 90 min and chased for 30 min, wild-type moPrP was resistant to digestion by endo H, and underwent a small but consistent increase in its electrophoretic mobility after digestion with neuraminidase (lanes 1-3) . This result is consistent with our previous demonstration that wild-type moPrP in CHO cells transits to the cell surface within 30 min after synthesis (11) . In contrast to the wild-type protein, T182A moPrP was endo H-sensitive and neuraminidase-resistant under the same conditions (lanes 4 -6), suggesting the this mutant polypeptide failed to reach the mid-Golgi. Surprisingly, T198A moPrP was endo H-resistant and neuraminidase-sensitive (lanes 6 -9), indicating that it transited as far as the trans-Golgi network; because of the small size of the mobility shift induced by neuraminidase, it was not possible to estimate whether all or only a fraction of the molecules became sialylated. The broadness of the 31-kDa band is also consistent with the acquisition of terminal sugar modifications on at least some of the molecules. As expected, moPrP carrying the double mutation T182A/T198A was not glycosylated, and was therefore not digestible by either enzyme (lanes 10 -12) .
T198A moPrP, but Not the Other Mutant moPrPs, Is Present on the Cell Surface-The glycosidase experiments suggested that the two singly glycosylated mutants, T182A and T198A, might differ in their cellular localization. To directly test this possibility, we carried out immunocytochemical staining of intact cells to detect the presence of moPrP on the cell surface. As expected, cells expressing wild-type moPrP displayed intense plasma membrane staining (Fig. 4A) . In contrast, cells expressing T182A moPrP were stained only at background levels (Fig.  4B) , consistent with our observation that this mutant protein fails to become endo H-resistant, and suggesting that it remains trapped intracellularly in a compartment proximal to the mid-Golgi. The double mutant T182A/T198A also apparently fails to reach the cell surface, as judged by lack of surface staining (Fig. 4D) . Cells expressing T198A moPrP displayed surface fluorescence that was distinctly higher than for cells expressing the other mutants (Fig. 4C) , consistent with the idea that at least some of the T198A molecules were transported to the plasma membrane following sialylation in the trans-Golgi network. The fact that the staining intensity was less than that of cells expressing wild-type moPrP, however, indicates that surface transport of T198A is inefficient.
To confirm these immunocytochemical observations, we analyzed surface expression of the moPrPs by assaying their accessibility to digestion by externally applied trypsin following metabolic labeling (Fig. 5, lanes 1-8) . We found that after 4 h of continuous labeling, 59% of wild-type moPrP and 34% of T198A moPrP were susceptible to digestion by trypsin, compared with ϳ5% for T182A and T182A/T198A moPrPs (Table  I) . Additional evidence that T198A moPrP was present on the cell surface is the fact that it can be labeled by biotinylation of intact cells with the membrane-impermeant reagent sulfo-biotin-X-NHS (Fig. 6C, lane 6) . 1-8) or presence (lane 9) of tunicamycin (5 g/ml). PrP was immunoprecipitated from cell lysates and analyzed by SDS-PAGE. Prior to immunoprecipitation, some samples were treated with N-glycosidase F (ϩ lanes). Brackets indicate the positions of the unglycosylated (0), singly glycosylated (1), and doubly glycosylated (2) distinguished from PrP C based on several biochemical properties, including: 1) insolubility in non-denaturing detergents (33); 2) relative resistance to digestion by proteinase K, which produces a core fragment of 27-30 kDa (33); 3) failure to be released from the cell surface by treatment with the GPI anchor-cleaving enzyme PIPLC (23, 34) ; and 4) retention in the detergent phase after PIPLC digestion and Triton X-114 phase partitioning (11, 27) . We have shown previously that PrP molecules carrying disease-related mutations acquire all four of these properties when expressed in CHO cells (11, 23, 26, 27) . We have hypothesized that the last two properties are related to the existence of a secondary mechanism of membrane attachment in addition to the GPI anchor, and to a conformational alteration of the protein that renders the GPI anchor partially inaccessible to PIPLC (11, 27) .
We tested whether the three moPrP glycosylation mutants acquired each of these PrP Sc -like properties. We assessed detergent-insolubility by centrifuging lysates of metabolically labeled CHO cells at 265,000 ϫ g for 40 min, a protocol that sediments PrP Sc but not PrP C . Under these conditions, 35-50% of T182A, T198A, and T182A/T198A moPrPs sedimented, compared with 3% for wild-type moPrP ( Fig. 6A and Table I ).
To test protease resistance, proteins methanol-precipitated from cell lysates were treated for 10 min with 3.3 g/ml proteinase K (Fig. 6B) . We observed that T182A, T198A, and T182A/T198A moPrPs were cleaved by the protease to yield a fragment that migrated around 24 kDa (lanes 4, 6, and 8) , while under the same conditions wild-type moPrP was completely degraded (lane 2). The fragment produced by digestion of the three glycosylation mutants has a smaller molecular mass than PrP 27-30, the protease-resistant core of PrP Sc from brain, presumably because the proteins from which they are derived are underglycosylated. Indeed, the fact that all three mutants produced a fragment of similar size suggests that the protease-resistant core was derived primarily from the unglycosylated form of each protein, a conclusion that is confirmed by the lack of effect of tunicamycin on the mobility of the fragments (data not shown).
Because T198A is the only one of the three mutant PrPs to be expressed on the cell surface (see above), this is the only one that could be tested for its susceptibility to release by PIPLC. We found that T198A molecules labeled by surface biotinylation were almost completely retained on the cell surface following treatment with PIPLC (Fig. 6C, lanes 5 and 6) , in contrast to wild-type molecules, the majority of which were released into the medium (Fig. 6C, lanes 1 and 2) (Table I) . Interestingly, the small amount of unglycosylated wild-type moPrP that was detectable on the cell surface in some experiments was not released by PIPLC (Fig. 6C, lane 2) . As expected from their inaccessibility to surface staining and trypsin digestion, both Thr 182 and T182A/T198A moPrPs were not labeled by surface biotinylation (Fig. 6C, lanes 3, 4, 7, and 8) .
When we treated Triton X-114 lysates of metabolically labeled cells with PIPLC and then partitioned them at 37°C, we found that ϳ60 -70% of each of the three mutant PrPs were retained in the detergent phase, while wild-type PrP was shifted almost entirely into the aqueous phase ( Fig. 6D and Table I ). We noted that the M r of mutant PrP molecules left in the detergent phase was slightly less than that of molecules shifted into the aqueous phase. Since removal of the GPI anchor produces a characteristic increase in the M r of PrP (11), this size differential is an indication that, under the conditions of the assay, some of the detergent-retained molecules may not have had their GPI anchors cleaved by PIPLC. 3 Taken together, our results indicate that T182A, T198A, and T182A/T198A moPrPs display the major biochemical hallmarks of PrP Sc . Of note, the degree of detergent-insolubility, protease-resistance, PIPLC-releasability, and Triton X-114 retention of these three proteins are quantitatively similar to those of six mutant moPrPs with disease-related mutations that we have previously analyzed in CHO cells (23, 35) .
Wild-type moPrP Synthesized in the Presence of Tunicamycin Is Transported to the Cell Surface and Acquires Limited PrP
Sclike Properties-The three mutations we have analyzed could modify the properties of PrP by virtue of their effect on glycosylation of the protein, and independently by perturbing the conformation of the polypeptide chain. To determine the relative contribution of these two factors we analyzed wild-type moPrP molecules synthesized in the presence of the glycosylation inhibitor tunicamycin.
We found that tunicamycin did not interfere with the transport of moPrP to the cell surface, as demonstrated by the following results. First, cells treated for 16 h with tunicamycin and analyzed by immunofluorescence microscopy showed surface staining that was only slightly less intense than for control cells (Fig. 4E) . The fluorescent signal was not due to wild-type moPrP molecules that had escaped the action of tunicamycin, since very little fully glycosylated moPrP remained after overnight incubation with the drug (see Fig. 7B, lane 3) . Second, the same percentage of PrP synthesized with or without tunicamycin was digested by externally applied trypsin (Fig. 5, lanes 1,  2, 9 , and 10; and Table I ). Third, it was possible to label moPrP in tunicamycin-treated cells by surface biotinylation (Fig. 7C,  lane 4) .
Surprisingly, we found that wild-type moPrP synthesized in the presence of tunicamycin displayed to a limited extent some, but not all, of the biochemical properties of PrP Sc . Approximately 15% of the protein from the inhibitor-treated cells was found in the pellet after ultracentrifugation, and a similar proportion partitioned into the Triton X-114 phase after PI-PLC treatment, values that are significantly different from those for untreated cells (Fig. 7, A and D; Table I ). Virtually all of the moPrP synthesized in the presence of tunicamycin was retained on the cell surface after treatment with PIPLC ( Fig.   7C ; Table I ). Thus, the protein synthesized in the presence of tunicamycin displays three of the biochemical properties of PrP Sc , although the degree of detergent-insolubility and hydrophobicity in the Triton X-114 assay are less than for the three mutant moPrPs (Table I) . When we tested the proteinase K sensitivity of moPrP molecules synthesized in the presence of tunicamycin, we were unable to detect a protease-resistant fragment (Fig. 7B, lane 4) .
To confirm these results in another cell type, we performed Panel A, lysates of CHO cells metabolically labeled for 3 h were centrifuged at 265,000 ϫ g to separate detergent-soluble from detergent-insoluble molecules. MoPrP in supernatant (S) and pellet (P) fractions was immunoprecipitated and separated by SDS-PAGE. Prior to immunoprecipitation, samples were enzymatically deglycosylated to produce a single band of PrP that could be more easily quantitated. Panel B, proteins methanol-precipitated from detergent lysates of CHO cells were left undigested (Ϫ lanes), or were treated with proteinase K (3.3 g/ml) at 37°C for 10 min (ϩ lanes). Proteins were then separated by SDS-PAGE and immunoblotted using antibody 3F4. Four times as many cell equivalents were loaded in the ϩ lanes as in the Ϫ lanes. Panel C, cells were surface-biotinylated and then treated with PIPLC at 4°C. MoPrP in PIPLC incubation media (M) and cell lysates (C) was immunoprecipitated, separated by SDS-PAGE, and then visualized by developing blots of the gels using horseradish peroxidase-coupled streptavidin and enhanced chemiluminescence. Panel D, lysates of CHO cells metabolically labeled for 20 min were subjected to Triton X-114 phase partitioning. MoPrP in aqueous (A) and detergent (D) phases was immunoprecipitated after enzymatic deglycosylation and separated by SDS-PAGE.
the same experiments on endogenous moPrP synthesized by untransfected mouse N2a neuroblastoma cells that had been treated with tunicamycin. We found that this protein behaved similarly to the one from inhibitor-treated CHO cells, in terms of its detergent-insolubility, PIPLC-releasability, and hydrophobicity in the Triton X-114 assay (results not shown).
DISCUSSION
N-Linked glycosylation of PrP is likely to play a critical role in prion biology, based on recent evidence that this modification may be a marker of prion strain diversity (20 -22) , and that an inherited form of spongiform encephalopathy is associated with mutational inactivation of one of the two consensus sites for N-glycosylation (18) . To explore the role of N-glycosylation in PrP metabolism, we have carried out a detailed analysis of transfected CHO cells that express abnormally glycosylated forms of PrP, generated either by substitution of alanine for threonine in one or both of the N-X-T consensus sites, or by synthesis in the presence of tunicamycin. We report here that PrPs carrying glycosylation site mutations display all of the biochemical properties of PrP Sc , and that wild-type PrP synthesized in the presence of tunicamycin exhibits a subset of these properties to a limited extent. Our results suggest that the PrP molecule has an intrinsic tendency, promoted by the absence of N-linked glycans, to become detergent-insoluble, PIPLC non-releasable, and hydrophobic, but that these properties do not become prominent unless the protein is converted to the PrP Sc state as a result of mutation.
Biosynthesis and Trafficking of Abnormally Glycosylated
PrP-We first characterized the metabolism and localization of PrP molecules lacking one or both N-linked oligosaccharide chains. Our results suggest that the two glycosylation consensus sites are not equivalent in terms of the effect that mutagenesis of these sites has on the trafficking of PrP. Inactivation of the site surrounding asparagine 180 (in T182A moPrP) blocked delivery of the protein to the cell surface. The intracellular compartment where this protein resides remains to be determined, but it is likely to be proximal to the mid-Golgi stack since the mutant protein remained sensitive to endo H. The double mutant T182A/T198A moPrP was also absent from the cell surface, and it is possible that its transit is blocked at the same point as T182A moPrP.
In contrast, mutation of the site surrounding asparagine 196 (in T198A moPrP) reduced, but did not completely prevent, delivery of the protein to the plasma membrane. Based on the relative surface staining intensity of cells expressing T198A moPrP compared with cells expressing equivalent amounts of wild-type moPrP (Fig. 4) , and on the fact that only about 30% of the T198A protein was susceptible to trypsin digestion compared with about 60% for the wild-type protein (Table I) , we estimate that only about half of the mutant molecules reach the cell surface after synthesis. The localization of those molecules that fail to reach the plasma membrane remains to be determined, but it is likely that they reside in a compartment distal to the mid-Golgi, based on the fact that virtually all of the mutant molecules became endo H-resistant.
Treatment of cells with tunicamycin did not appreciably affect delivery of wild-type moPrP to the cell surface. This indicates that N-linked glycans are not necessary for normal biosynthetic trafficking of PrP. This conclusion, which was also reached by Petersen et al. (12) , is consistent with the observa- tion that an unglycosylated form of wild-type PrP is often detectable on the plasma membrane in the absence of any inhibitors (Fig. 6C, lanes 1 and 2; see also Ref. 10) . Although inhibition of glycosylation causes many glycoproteins to misfold, resulting in their retention and degradation in a pre-Golgi compartment, there are a number of proteins in addition to PrP whose maturation is unaffected by the absence of oligosaccharide modification (14) .
Our results on the biosynthesis and trafficking of moPrP glycosylation mutants in CHO cells are similar in most respects to those of Rogers et al. (25) who analyzed a homologous set of hamster PrP mutants in CV1 cells. In contrast to us, however, they failed to detect any of the mutant proteins on the cell surface, and they speculated that the absence of oligosaccharide chains per se was responsible for this effect. This contention seems unlikely in light of our demonstration that T198A moPrP as well as wild-type moPrP in the presence of tunicamycin both reach the cell surface.
Scrapie-like Properties of Aberrantly Glycosylated PrP-We found that T182A, T198A, and T182A/T198A moPrPs each exhibited three of the four operational properties that we have used previously to define the PrP Sc state: 1) insolubility in Triton/deoxycholate; 2) production of a protease-resistant core fragment after digestion with proteinase K; and 3) retention in the Triton X-114 detergent phase after PIPLC treatment. T198A moPrP was the only mutant that could be assayed for the fourth property, retention on the cell surface after PIPLC treatment, since this was the only one of the proteins that was expressed on the plasma membrane, and it was found to be PIPLC non-releasable. The T182A mutation is homologous to one in human PrP that has recently been found in a Brazilian family with an inherited spongiform encephalopathy (18) . The fact that a moPrP molecule carrying this mutation acquires PrP Sc -like properties is therefore consistent with our previous work showing that six other disease-related mutations, but not a non-pathogenic amino acid substitution, induced a PrP Sc -like state when expressed in cultured CHO cells (23, 35) . We do not yet know whether mutant PrPs synthesized in CHO cells are infectious. Although no individuals carrying a mutation homologous to T198A have yet been described, we would predict that such individuals might be found in the future.
Our results have implications for the cellular location at which PrP Sc is generated. The fact that T182A and T182A/ T198A moPrPs are converted to a PrP Sc -like state without being expressed on the cell surface indicates that transit to the plasma membrane is not necessary for the conversion process. This conclusion is consistent with our recent studies of another mutant PrP which indicate that the earliest step in generation of PrP Sc occurs in the endoplasmic reticulum during or very soon after synthesis of the polypeptide chain, and is manifested by retention of the protein in the Triton X-114 phase after PIPLC treatment (27) . This change is followed later by acquisition of detergent insolubility and protease resistance, steps that normally take place subsequent to arrival of the newly synthesized protein at the plasma membrane, but which can occur intracellularly in cells treated with brefeldin A. The conclusion that emerges from our studies, as well as ones using scrapie-infected neuroblastoma cells (15) , is that PrP Sc production can occur in any of several cellular compartments, depending on the protein being expressed and the presence of pharmacological agents. It is noteworthy that none of six other disease-related mutations that we have analyzed previously markedly altered the efficiency with which PrP is delivered to the cell surface (11, 23, 35 ). These mutations include five single amino acid substitutions and one insertion, covering both Nterminal and C-terminal halves of the molecule. This comparison suggests that defects in biosynthetic trafficking are not a general feature of pathologic mutations in PrP, and are not necessary for generation of PrP Sc . For the T198A mutant, which exhibits only a partial block in cell surface delivery, it may be the retained or non-retained molecules, or both, that are converted to the PrP Sc state. Surprisingly, wild-type PrP synthesized in the presence of tunicamycin displayed several biochemical attributes of PrP Sc , although less prominently than the mutant PrPs. We were unable to detect any protease-resistant PrP in tunicamycintreated cells, although ϳ15% of the protein was detergentinsoluble after ultracentrifugation and hydrophobic in the Triton X-114 assay, and most of it was retained on the cell surface after treatment with PIPLC. These results raise the question of whether some of the PrP synthesized in the presence of tunicamycin might have undergone the conformational transition to authentic PrP Sc . We think that this is unlikely for at least two reasons. First, unglycosylated wild-type PrP constitutes 5-10% of the PrP synthesized in cells normally, and it would be surprising if these molecules represented PrP Sc . This small population of unglycosylated PrP in control cells was poorly released by PIPLC (Fig. 6C, lanes 1 and 2) , suggesting that it is similar to PrP synthesized in tunicamycin-treated cells. (We have not tested these molecules for other PrP Sc -like properties.) Second, wild-type PrP molecules from tunicamycintreated cells are clearly less "scrapie-like" than mutant PrP molecules. All seven mutant PrPs associated with familial spongiform encephalopathies that we have analyzed in CHO cells thus far (six published previously (23, 35) and T182A presented here) produce protease-resistant fragments, and they all display a degree of detergent-insolubility and hydrophobicity in Triton X-114 that are greater than those of wildtype PrP synthesized in the presence of tunicamycin. T182A/ T198A moPrP, which carries no N-linked glycans, is also distinct in its trafficking and biochemical properties from unglycosylated wild-type protein made in inhibitor-treated cells. We conclude from these comparisons that alteration of the amino acid sequence changes the state of PrP in a way that inhibition of glycosylation alone does not. We have noted previously that some PrP molecules carrying pathogenic mutations display an altered glycoform distribution, with a shift toward less glycosylated forms (23, 35) . In light of the discussion here, we would suggest that the PrP Sc -like properties of these molecules are determined directly by mutation-induced alterations in protein conformation rather than indirectly via a change in glycosylation state.
There (36, 37) . One might expect these species to possess some but not all of the biochemical markers of PrP Sc , or display these markers to a quantitatively more limited extent. The amount of this intermediate may be undetectable in normal cells, but its amount might be increased in tunicamycin-treated cells because the absence of N-linked glycans favors the transition from PrP C to PrP * . A second possible explanation is that the PrP molecule has an intrinsic propensity to adopt certain of the biochemical attributes of PrP Sc even when it is in the PrP C state, and that glycosylation tends to prevent this. In this view, the biochemical markers we and others commonly use to recognize PrP Sc are not unique to that isoform, although conversion to the PrP Sc state significantly accentuates these operational properties. A third possibility is that the insolubility and PIPLC resistance we observe in unglycosylated PrP are not directly related to the formation of PrP Sc , and that they simply reflect changes in physical properties that might occur in any glycoprotein synthesized without its normal complement of oligosaccharide chains. It is well known, for example, that the polarity of N-glycans enhances the solubility of proteins to which they are attached, and that their absence can promote aggregation (14) .
Regardless of which of these explanations should prove to be correct, our results are consistent with several pieces of evidence suggesting that unglycosylated molecules are somehow preferred, either as substrates or products, in the formation of PrP Sc . PrP Sc is produced more rapidly in scrapie-infected neuroblastoma cells treated with tunicamycin (15) , and PrP Sc synthesized in infected cells in the absence of inhibitor is enriched in lower M r glycoforms (13, 16) . We have also noted that PrP molecules carrying some disease-related mutations display a preponderance of singly glycosylated and unglycosylated forms when expressed in CHO cells (23) . Finally, unglycosylated PrP appears to be a particularly efficient substrate for PrP Sc production in an in vitro system (17) .
Recent evidence has suggested that different strains of prions can be distinguished by distinctive patterns of glycosylation (20 -22) . Since not all strains of PrP Sc are enriched for less glycosylated species, factors other than the intrinsic convertibility of unglycosylated PrP must clearly play a role in determining glycoform distribution. These factors might include selective degradation of specific glycoforms (12) , enzymatic removal or modification of glycan chains, and targeting of strains to distinct neuronal populations that contain characteristic arrays of glycosyl transferases (24) . Furthermore, although we have shown that the complete absence of N-linked glycans favors acquisition of limited PrP Sc attributes, it is possible that subtle variations in the structure or composition of the oligosaccharide chains also modulate the properties of the protein, thereby expanding the range of possible glycoform signatures that could characterize different PrP Sc strains. Finally, it is conceivable that the glycosylation pattern of each strain reflects the conformation of the PrP polypeptide chain at the time that oligosaccharide chains were added in the endoplasmic reticulum and modified in the Golgi. If PrP molecules were already folded in a strain-specific way early in the biosynthetic pathway, then it is easy to imagine how each strain might acquire a characteristic array of glycan modifications.
It will be important now to distinguish among these possible alternatives for the generation of glycoform diversity in prion strains. A number of experimental strategies are available for this task, including propagation of PrP Sc in cell lines that are deficient or overactive in specific steps of the glycosylation pathway, enzymatic modification of the glycan chains of purified PrP Sc , and use of additional glycosylation inhibitors and mutant PrPs. The results presented here form an important background for this work by demonstrating that inhibition of glycosylation modifies the biochemical properties of PrP, but in a way that is distinct from the effects of altering the amino acid sequence.
